The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Effectiveness of targeting HER2 in heavily pretreated patients with occult HER2-positive (tissue-negative, serum-positive and/or HER2-positive circulating tumor cells) metastatic breast cancer in the clinical routine.
 
Christian M. Kurbacher
Honoraria - Amgen; Fresenius Biotech; Novartis; Teva
Research Funding - Amgen (Inst); Fresenius Biotech (Inst); Hexal (Inst); Medac (Inst); Novartis (Inst); Roche Pharma AG (Inst); Teva (Inst)
 
Annegret Quade
No Relationships to Disclose
 
Gerhard Kunstmann
No Relationships to Disclose
 
Susanne Herz
No Relationships to Disclose
 
Jutta A. Kurbacher
Honoraria - Amgen (I); Fresenius Biotech (I); Novartis (I); Teva (I)
Research Funding - Amgen (I); Fresenius Biotech (I); Hexal (I); Medac (I); Novartis (I); Roche Pharma AG (I); Teva (I)
 
Mathias A. Warm
Employment - Celgene (I)
Honoraria - Celgene
Research Funding - Amgen (Inst); Celgene (Inst); Novartis (Inst); Roche Pharma AG (Inst)